Study of liver inflammation and scarring in hepatitis B or fatty liver
Part of Digestive system, Infections clinical trials.
This study looks at what factors predict liver inflammation, scarring (fibrosis), and health outcomes in people with long-term hepatitis B or fatty liver disease. The goal is to better understand who is more likely to worsen over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 years old or older
- Have hepatitis B surface antigen (HBsAg) positive for at least 6 months, and no other hepatitis viruses
- Have nonalcoholic fatty liver disease (NAFLD) confirmed by imaging, blood/predictive tests, or a liver biopsy
- Do not have other chronic liver causes (like alcohol-related liver disease, other viral hepatitis, or medicine-related liver injury)
- Have no history of liver cancer (HCC) or other cancers before your liver biopsy
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows people who have chronic hepatitis B and also have fat buildup in the liver (nonalcoholic fatty liver disease). It’s looking at how these conditions behave over time and what may help, using information collected during follow-up visits.
This study is looking for new ways to detect liver scarring (fibrosis) in people with fatty liver disease (NAFLD, NASH, MASLD, or MASH). If you qualify, you will give a blood sample to help identify biomarkers that could replace biopsies.
This study follows people who have been confirmed to have fatty liver disease seen on a liver sample. It aims to understand the condition over time and how different causes and health factors may affect it.
This study looks at what drives non-alcoholic fatty liver disease and how it affects the body, including immune-related changes. You may be invited if you have confirmed fatty liver disease or, alternatively, if you are a healthy person with no liver disease.
This study looks at better ways to predict significant liver fibrosis (scarring) in people with chronic hepatitis B or non-alcoholic fatty liver disease. It aims to help avoid invasive tests like liver biopsy.
This study looks at how the liver's immune environment changes in people with non-alcoholic fatty liver disease (NAFLD) that has progressed to significant scarring. Researchers will use a liver biopsy to understand the inflammation better, which may lead to new treatments.
Hear when a new Chronic Hepatitis B trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.